SRR975596
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- HEDGEHOG_SIGNALING+0.420
- HYPOXIA+0.410
- WNT_BETA_CATENIN_SIGNALING+0.370
- MYOGENESIS+0.350
- APICAL_JUNCTION+0.330
- ANGIOGENESIS+0.300
- TGF_BETA_SIGNALING+0.280
- TNFA_SIGNALING_VIA_NFKB+0.270
- CHOLESTEROL_HOMEOSTASIS+0.240
Top 10 suppressed
- G2M_CHECKPOINT-0.450
- INTERFERON_ALPHA_RESPONSE-0.440
- E2F_TARGETS-0.420
- INTERFERON_GAMMA_RESPONSE-0.380
- IL6_JAK_STAT3_SIGNALING-0.350
- OXIDATIVE_PHOSPHORYLATION-0.350
- FATTY_ACID_METABOLISM-0.320
- PROTEIN_SECRETION-0.310
- PANCREAS_BETA_CELLS-0.260
- ALLOGRAFT_REJECTION-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R7 | — | — | 0.858 |
| 2 | 3843de1d-0eaa-48af-be58-903fcf2e5f89 | — | — | 0.842 |
| 3 | R314 | — | — | 0.827 |
| 4 | SRR2932826 | — | — | 0.806 |
| 5 | SRR5088831 | — | — | 0.786 |
| 6 | SRR8613703 | — | D | 0.784 |
| 7 | TCGA-56-8626-01A-11R-2403-07 | — | cohortSQ1 | 0.770 |
| 8 | SRR27320666 | — | — | 0.768 |
| 9 | TCGA-BA-6868-01B-12R-1915-07 | — | — | 0.761 |
| 10 | R302 | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| HYPOXIA | 0.410 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |